Factores nutricionales asociados al padecimiento de hipertensión arterial en adultos que consultan en la UCSF Doctor Alberto Aguilar Rivas; Santa Tecla, La Libertad Mayo-Julio de 2017

En la actualidad vivimos en un entorno que cambia rápidamente. Sobre la salud humana influyen en todo el mundo factores poderosos, como el envejecimiento de la población, urbanización acelerada y la generalización de modos de vida poco saludables. Cada vez más, los países ricos y pobres se enfrentan a los mismos problemas de salud. Hoy en día las enfermedades no transmisibles, como las enfermedades cardiovasculares, han superado a las enfermedades infecciosas como principales causas de mortalidad a nivel mundial. Uno de los factores de riesgo clave de las enfermedades cardiovasculares es la Hipertensión Arterial (presión arterial elevada). La Hipertensión Arterial (HTA), es una enfermedad crónica degenerativa que en los últimos años ha afectado a un considerable porcentaje de la población mundial y local. Los factores asociados al riego de padecer Hipertensión Arterial son múltiples por lo cual hay un interés en esclarecer la relación de estos con esta enfermedad. Diversas instituciones de gran calibre internacional como la Organización Mundial de la salud (OMS), la Asamblea general de las Naciones Unidad, la Organización Panamericana de la Salud (OPS) han despertado un particular interés en la comunidad mundial para que se reconozcan en cada país o región, los factores que se encuentran asociados a enfermedades crónicas no transmisibles (ECNT), como lo es la hipertensión arterial, para que la población indague, conozca y se informe acerca de los diversos factores vinculados a ECNT, las repercusiones devastadoras de estas, y que finalmente puedan adoptar medidas o estrategias encaminadas a reducirlas de formar individual o colectiva

Microalgal biorefineries

ABSTRACT: Microalgae-based bioproducts remain expensive mainly due to microalgae cultivation, harvesting, and downstream processing costs. Nonetheless, microalgae are a high potential source of several biofuels, biofertilizers, and bioproducts (e.g., carbohydrates, long-chain fatty acids, pigments, and proteins), which can provide important nutritional, cosmetical, pharmaceutical, and health benefits. In addition, they are able to perform wastewater bioremediation and carbon dioxide mitigation. This not only contributes to a more sustainable microalgae production, with environmental benefits, but also offers cost savings on the whole process. Hence, from these small cellular factories, a large source of compounds and products can be obtained, providing a real microalgal-based biorefinery. This type of approach is crucial for the full application and commercialization of microalgae in a large range of products and industries, with added benefits for bioeconomy and society in general. This chapter addresses the potential transformation of microalgal biomass into a wide range of marketable products, presenting examples of experimental microalgae-based biorefineries grown in an autotrophic mode at a laboratory scale.info:eu-repo/semantics/publishedVersio

Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study

Background Approximately 450 000 children are born with familial hypercholesterolaemia worldwide every year, yet only 2·1% of adults with familial hypercholesterolaemia were diagnosed before age 18 years via current diagnostic approaches, which are derived from observations in adults. We aimed to characterise children and adolescents with heterozygous familial hypercholesterolaemia (HeFH) and understand current approaches to the identification and management of familial hypercholesterolaemia to inform future public health strategies. Methods For this cross-sectional study, we assessed children and adolescents younger than 18 years with a clinical or genetic diagnosis of HeFH at the time of entry into the Familial Hypercholesterolaemia Studies Collaboration (FHSC) registry between Oct 1, 2015, and Jan 31, 2021. Data in the registry were collected from 55 regional or national registries in 48 countries. Diagnoses relying on self-reported history of familial hypercholesterolaemia and suspected secondary hypercholesterolaemia were excluded from the registry; people with untreated LDL cholesterol (LDL-C) of at least 13·0 mmol/L were excluded from this study. Data were assessed overall and by WHO region, World Bank country income status, age, diagnostic criteria, and index-case status. The main outcome of this study was to assess current identification and management of children and adolescents with familial hypercholesterolaemia. Findings Of 63 093 individuals in the FHSC registry, 11 848 (18·8%) were children or adolescents younger than 18 years with HeFH and were included in this study; 5756 (50·2%) of 11 476 included individuals were female and 5720 (49·8%) were male. Sex data were missing for 372 (3·1%) of 11 848 individuals. Median age at registry entry was 9·6 years (IQR 5·8–13·2). 10 099 (89·9%) of 11 235 included individuals had a final genetically confirmed diagnosis of familial hypercholesterolaemia and 1136 (10·1%) had a clinical diagnosis. Genetically confirmed diagnosis data or clinical diagnosis data were missing for 613 (5·2%) of 11 848 individuals. Genetic diagnosis was more common in children and adolescents from high-income countries (9427 [92·4%] of 10 202) than in children and adolescents from non-high-income countries (199 [48·0%] of 415). 3414 (31·6%) of 10 804 children or adolescents were index cases. Familial-hypercholesterolaemia-related physical signs, cardiovascular risk factors, and cardiovascular disease were uncommon, but were more common in non-high-income countries. 7557 (72·4%) of 10 428 included children or adolescents were not taking lipid-lowering medication (LLM) and had a median LDL-C of 5·00 mmol/L (IQR 4·05–6·08). Compared with genetic diagnosis, the use of unadapted clinical criteria intended for use in adults and reliant on more extreme phenotypes could result in 50–75% of children and adolescents with familial hypercholesterolaemia not being identified. Interpretation Clinical characteristics observed in adults with familial hypercholesterolaemia are uncommon in children and adolescents with familial hypercholesterolaemia, hence detection in this age group relies on measurement of LDL-C and genetic confirmation. Where genetic testing is unavailable, increased availability and use of LDL-C measurements in the first few years of life could help reduce the current gap between prevalence and detection, enabling increased use of combination LLM to reach recommended LDL-C targets early in life. Funding Pfizer, Amgen, Merck Sharp & Dohme, Sanofi–Aventis, Daiichi Sankyo, and Regeneron

Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study

Background: Approximately 450 000 children are born with familial hypercholesterolaemia worldwide every year, yet only 2·1% of adults with familial hypercholesterolaemia were diagnosed before age 18 years via current diagnostic approaches, which are derived from observations in adults. We aimed to characterise children and adolescents with heterozygous familial hypercholesterolaemia (HeFH) and understand current approaches to the identification and management of familial hypercholesterolaemia to inform future public health strategies. Methods: For this cross-sectional study, we assessed children and adolescents younger than 18 years with a clinical or genetic diagnosis of HeFH at the time of entry into the Familial Hypercholesterolaemia Studies Collaboration (FHSC) registry between Oct 1, 2015, and Jan 31, 2021. Data in the registry were collected from 55 regional or national registries in 48 countries. Diagnoses relying on self-reported history of familial hypercholesterolaemia and suspected secondary hypercholesterolaemia were excluded from the registry; people with untreated LDL cholesterol (LDL-C) of at least 13·0 mmol/L were excluded from this study. Data were assessed overall and by WHO region, World Bank country income status, age, diagnostic criteria, and index-case status. The main outcome of this study was to assess current identification and management of children and adolescents with familial hypercholesterolaemia. Findings: Of 63 093 individuals in the FHSC registry, 11 848 (18·8%) were children or adolescents younger than 18 years with HeFH and were included in this study; 5756 (50·2%) of 11 476 included individuals were female and 5720 (49·8%) were male. Sex data were missing for 372 (3·1%) of 11 848 individuals. Median age at registry entry was 9·6 years (IQR 5·8-13·2). 10 099 (89·9%) of 11 235 included individuals had a final genetically confirmed diagnosis of familial hypercholesterolaemia and 1136 (10·1%) had a clinical diagnosis. Genetically confirmed diagnosis data or clinical diagnosis data were missing for 613 (5·2%) of 11 848 individuals. Genetic diagnosis was more common in children and adolescents from high-income countries (9427 [92·4%] of 10 202) than in children and adolescents from non-high-income countries (199 [48·0%] of 415). 3414 (31·6%) of 10 804 children or adolescents were index cases. Familial-hypercholesterolaemia-related physical signs, cardiovascular risk factors, and cardiovascular disease were uncommon, but were more common in non-high-income countries. 7557 (72·4%) of 10 428 included children or adolescents were not taking lipid-lowering medication (LLM) and had a median LDL-C of 5·00 mmol/L (IQR 4·05-6·08). Compared with genetic diagnosis, the use of unadapted clinical criteria intended for use in adults and reliant on more extreme phenotypes could result in 50-75% of children and adolescents with familial hypercholesterolaemia not being identified. Interpretation: Clinical characteristics observed in adults with familial hypercholesterolaemia are uncommon in children and adolescents with familial hypercholesterolaemia, hence detection in this age group relies on measurement of LDL-C and genetic confirmation. Where genetic testing is unavailable, increased availability and use of LDL-C measurements in the first few years of life could help reduce the current gap between prevalence and detection, enabling increased use of combination LLM to reach recommended LDL-C targets early in life

A922 Sequential measurement of 1 hour creatinine clearance (1-CRCL) in critically ill patients at risk of acute kidney injury (AKI)

Meeting abstrac

Multi-ancestry genome-wide association meta-analysis of Parkinson?s disease

Although over 90 independent risk variants have been identified for Parkinson’s disease using genome-wide association studies, most studies have been performed in just one population at a time. Here we performed a large-scale multi-ancestry meta-analysis of Parkinson’s disease with 49,049 cases, 18,785 proxy cases and 2,458,063 controls including individuals of European, East Asian, Latin American and African ancestry. In a meta-analysis, we identified 78 independent genome-wide significant loci, including 12 potentially novel loci (MTF2, PIK3CA, ADD1, SYBU, IRS2, USP8, PIGL, FASN, MYLK2, USP25, EP300 and PPP6R2) and fine-mapped 6 putative causal variants at 6 known PD loci. By combining our results with publicly available eQTL data, we identified 25 putative risk genes in these novel loci whose expression is associated with PD risk. This work lays the groundwork for future efforts aimed at identifying PD loci in non-European populations

Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes

publisher: Elsevier articletitle: Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes journaltitle: Cell articlelink: https://doi.org/10.1016/j.cell.2018.05.046 content_type: article copyright: © 2018 Elsevier Inc

Structural analysis of a railway bridge using the FEM-DEM technique

The objectives of this work are focused on giving an answer to the problems presented in the operation of a railway bridge, using the FEM-DEM numerical technique considering static and dynamic loads. The purpose is to find out the existing breakage mechanisms in the bridge. From a social aspect, there is concern about the possible collapse of the bridge, with the corresponding economic loss and eventually human losses; therefore, the interest and social involvement of the study has repercussions not only on the repair mechanisms that can be adopted but also on the possible revision of the calculation and design aspects in this type of works. The FEM-DEM technique developed by Zárate et al. [1,2] has been validated in various laboratory tests [3-5]. Due to the characteristics of the problem, the technique used is an ideal tool to study the structural behaviour of the bridge from a static and dynamic point of view. Considering the reinforcing steel in the bridge is fundamental to carry out the structural analysis, which is why the implementation of this type of reinforcement in the FEM-DEM formulation is described. The paper is organized as follows. First, the problems found in the civil works under study are described. Subsequently, a small sketch of the FEM-DEM technique is made, and the inclusion of reinforcing steel is formulated. After that, the different results of the static and dynamic studies carried out are presented